<DOC>
	<DOCNO>NCT01516723</DOCNO>
	<brief_summary>Percutaneous recanalization total coronary occlusion ( TCO ) historically hamper high rate restenosis reocclusion . In PRISON II III trial show landmark reduction restenosis sirolimus-eluting stent ( Cypher , Cordis Corporation ) compare conventional bare metal stent TCO . In PRISON III trial , observe similar favourable result second-generation zotarolimus-eluting stent ( Resolute , Medtronic Inc. ) . Another drugs-eluting stent mount everolimus ( Xience Prime , Abbott ) also demonstrate favourable result TCO . Recently , drug-eluting stent ( DES ) bioresorbable polymer coating develop , address safety concern regard observation late stent thrombosis , due hypersensitivity reaction , chronic inflammation , durable polymer coating DES . However , none DES bioresorbable polymer evaluate patient TCO . The PRISON IV trial prospective , randomize , single-blinded , multi-center trial , design evaluate safety , efficacy , angiographic outcome hybrid sirolimus-eluting stent bioresorbable polymer ( ORSIRO , Biotronik Inc. ) compare everolimus-eluting stent durable polymer ( Xience Prime , Abbott ) patient successfully recanalized TCOs .</brief_summary>
	<brief_title>Hybrid Sirolimus-eluting Versus Everolimus-eluting Stents Total Coronary Occlusions</brief_title>
	<detailed_description>A total 330 patient randomize either hybrid sirolimus-eluting stent everolimus-eluting stent successful recanalization TCO . Clinical follow-up 1 , 6 , 12 month , 2 , 3 , 4 , 5 year angiographic follow-up 9 month . In 60 patient optical coherence tomography perform 9 month follow-up angiography . Quantitative coronary optical coherence tomography analysis perform two independent core laboratory . The primary end point in-segment late luminal loss 9 month angiographic follow-up . Secondary angiographic end point include follow ; in-stent luminal loss , acute recoil , acute gain , net luminal gain , late loss index , minimal lumen diameter , percentage diameter stenosis , in-stent in-segment binary restenosis reocclusions 9 month angiographic follow-up . Secondary clinical endpoint include composite major adverse cardiac event ( death , MI clinically driven target lesion revascularization ) ; clinically drive target vessel revascularisation ( TVR ) , target vessel failure ( cardiac death , MI , clinically drive TVR ) stent thrombosis 5 year clinical follow-up . Tertiary optical coherence tomography end point 9 month follow-up following : Percentage uncover stent strut , percentage malapposed stent strut , tissue strut thickness , absolute percentage intimal hyperplasia .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Stenosis</mesh_term>
	<mesh_term>Coronary Occlusion</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>INCLUSION CRITERIA : estimate duration occlusion least 4 week . sign ischemia relate occlude coronary artery . successful recanalization occlude artery achieve . reference diameter &gt; 2.5 mm . write informed consent obtain . EXCLUSION CRITERIA : primary rescue PCI acute myocardial infarction lesion could cross . lesion complex anatomy make successful stent deployment unlikely . guide wire true lumen distal occlusion . Sirolimus zotarolimus allergy venous arterial bypass graft pregnant nursing woman . participation trial . factor make longterm followup difficult unlikely . life expectancy &lt; 1 year . contraindication ASA Clopidogrel heparin . use coumadin could stop procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>drug-eluting stent</keyword>
	<keyword>chronic total occlusion</keyword>
	<keyword>hybrid sirolimus-eluting stent</keyword>
	<keyword>everolimus-eluting stent</keyword>
</DOC>